DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award | W81XWH 21 PRARP ADRA

Opportunity Information: Apply for W81XWH 21 PRARP ADRA

The DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award (FY21 PRARP ADRA; Funding Opportunity Number W81XWH 21 PRARP ADRA) is a Department of Defense research funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) that focuses on speeding up the development of clinically useful diagnostic and prognostic biomarkers for Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD), specifically in the context of military-relevant risk factors. The central goal is not to explore early-stage ideas, but to push the field toward biomarkers that are far enough along that they can be qualified and moved into clinical practice quickly, with a clear line of sight to real-world use in people affected by military exposures or experiences that may increase AD/ADRD risk.

A key feature of this award is its emphasis on biomarker qualification rather than biomarker discovery. In this program, “qualification” is described as an evidentiary process that connects a biomarker to underlying biology and to meaningful clinical endpoints. In other words, it is not enough to show that a marker changes in a lab assay; applicants are expected to show that the biomarker has a defensible relationship to disease processes and to outcomes that matter clinically, such as cognitive performance and/or relevant behavior. Projects can include elements of biomarker validation, but only as they support qualification. Validation here is defined in measurement terms, including reproducibility, accuracy, precision, and sensitivity limits. If a proposal includes validation work, it needs to be framed as a step that strengthens the overall qualification case rather than as a standalone technical exercise.

The program is explicitly human-based, and basic biomarker discovery is not supported. Animal research is prohibited, which signals that the award is intended for studies that are already grounded in human biology, human samples, and human clinical outcomes. The biomarker under study must correlate with clinical endpoints that include cognition and/or behavior, and the research must be tied to a military risk factor identified in the application. This focus pushes applicants to design studies where the biomarker is evaluated in the context of the exposures and populations the DoD cares about, rather than in generic Alzheimer’s cohorts that may not reflect military-related risks.

In terms of the kinds of diagnostics the program is interested in, the announcement encourages several practical modalities, including fluid-based biomarkers (for example, blood or other biofluids), imaging-based approaches, retinal measures, and wearable devices. This reflects a preference for tools that could plausibly be deployed in clinics and health systems, potentially including settings relevant to active duty, veterans, or other DoD-connected populations. Across these modalities, the expectation is that the proposed biomarker will improve diagnostic and/or prognostic performance, particularly specificity and sensitivity for AD/ADRD outcomes.

Operational feasibility is treated as a major review consideration. Applications must include a concrete plan demonstrating access to an appropriate cohort and a credible participant accrual strategy. The cohort must be suitable for the military risk factor being studied, and the studies must prospectively recruit participants, rather than relying solely on existing retrospective datasets. Applicants also need to make the case that the project will deliver attributable outcomes in the short term (meaning results that clearly come from the proposed work), while also articulating the longer-term scientific gains, such as how the biomarker could be used in future trials, screening approaches, or risk stratification for AD/ADRD in military-relevant groups.

From an applicant and administrative standpoint, the opportunity is listed as discretionary and open to an unrestricted set of eligible applicants (in practice meaning any organization type is allowed, subject to any additional eligibility notes in the full announcement). Funding instruments include grants and cooperative agreements under the Science and Technology / Research and Development category (CFDA 12.420). The original posting date was April 8, 2021, with an original closing date of July 21, 2021, and the opportunity anticipated making one award. The award ceiling is listed as 0 in the summary data, which typically indicates that applicants must rely on the full program announcement for the actual budget limits or that a fixed ceiling was not captured in that particular listing.

Overall, the FY21 PRARP ADRA is designed for teams that can credibly bridge military risk factor research and Alzheimer’s disease expertise, with the Principal Investigator expected to demonstrate that the team has experience in both areas. The program is impact-driven by design: it prioritizes projects that can produce strong evidence tying a biomarker to AD/ADRD-relevant clinical outcomes in humans, in a way that supports qualification and rapid translation into clinical practice, rather than exploratory or preclinical biomarker discovery work.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 08, 2021.
• Applicants must submit their applications by Jul 21, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PRARP ADRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: